Alamar Biosciences Inc (ALMR) FinancialsALMRAlamar Biosciences Inc

Alamar Biosciences Inc (ALMR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Services, accounting for 120.9% of total sales, equivalent to $35.59M. Other significant revenue streams include Consumables and Instruments. Understanding this composition is critical for investors evaluating how ALMR navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Alamar Biosciences Inc maintains a gross margin of 60.21%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -45.98%, while the net margin is -44.85%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ALMR converts its operational activities into shareholder value.

In the context of the broader market, ALMR competes directly with industry leaders such as URGN and KLRA. With a market capitalization of $2.30B, it holds a significant position in the sector. When comparing efficiency, ALMR's gross margin of 60.21% stands against URGN's 90.93% and KLRA's N/A. Such benchmarking helps identify whether Alamar Biosciences Inc is trading at a premium or discount relative to its financial performance.

The company has shown strong revenue growth, with Q2 2026 revenue of $29.4 million, up 82% year-over-year, and gross margins improving to 60.21%.